North America Point of Care Molecular Diagnostics Market

North America Point of Care Molecular Diagnostics Market Size, Share & Industry Trends Analysis Report By Product & Service (Assays & Kits, Instruments & Analyzers and Software & Services), By End User, By Technology, By Application, By Country and Growth Forecast, 2023 - 2030

Report Id: KBV-16035 Publication Date: June-2023 Number of Pages: 113
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The North America Point of Care Molecular Diagnostics Market would witness market growth of 9.5% CAGR during the forecast period (2023-2030).

The healthcare system in the United States is sophisticated and well-organized. Additionally, the system supports R&D. The regulations promote foreign companies' entry into the US and the North American market. A large increase has also aided the growth of the market in new introductions. Molecular diagnostics has led the response to the COVID-19 pandemic. for instance, a study titled "Point-of-Care PCR Assays for COVID-19 Detection" published in the US National Library of Medicine claimed that reverse transcriptase-polymerase chain reaction (RT-PCR) and the quantitative variant (qRT-PCR) were considered the gold standard for COVID-19 diagnosis. However, there are several restrictions on molecular diagnostic technology.

As an instance, a research paper titled "Molecular diagnostic technologies for COVID-19: Limitations and challenges," published in the US National Library of Medicine in November 2020, explained that modern molecular diagnostics are not intended for point-of-care diagnosis of COVID-19 however, offer a core diagnostic solution for carrying out a large number of tests in a reasonable amount of time. Therefore, a precise diagnosis is essential to stop the spread of the illness. Such investigations deepen our understanding of the uses and constraints of molecular diagnostic tools. Product introductions are another component in the market's expansion.

The United States has the highest rate of cancer prevalence. The American Cancer Society estimates that 608,570 cancer deaths and 1,898,160 new cancer cases will be diagnosed in the United States in 2021. The same source also said that 90,222 cancer-related fatalities and 195,499 new cancer cases are anticipated in Mexico in 2020. The market is anticipated to grow even more due to the region's strong demand being matched by companies.

The US market dominated the North America Point of Care Molecular Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,103.2 million by 2030. The Canada market is showcasing a CAGR of 11.9% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 11% during (2023 - 2030).

Based on Product & Service, the market is segmented into Assays & Kits, Instruments & Analyzers and Software & Services. Based on End User, the market is segmented into Physicians Offices, Hospitals & ICUs, Research Institutes and Others. Based on by Technology, the market is segmented into RT-PCR, Isothermal Nucleic Acid Amplification Technology (INAAT) and Others. Based on Application, the market is segmented into Respiratory Diseases, Hospital-acquired Infections, Sexually Transmitted Diseases, Cancer, Hepatitis, Gastrointestinal Disorders and Others.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Worldwide Point of Care Molecular Diagnostics Market is Projected to reach USD 4.1 Billion by 2030, at a CAGR of 10.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Qiagen N.V., Danaher Corporation, Bio-Rad Laboratories, Inc., BioMerieux S.A., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., and Nova Biomedical Corporation.

Scope of the Study

Market Segments Covered in the Report:

By Product & Service

  • Assays & Kits
  • Instruments & Analyzers
  • Software & Services Surveillance & Monitoring

By End User

  • Physicians Offices
  • Hospitals & ICUs
  • Research Institutes
  • Others

By Technology

  • RT-PCR
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Others

By Application

  • Respiratory Diseases
  • Hospital-acquired Infections
  • Sexually Transmitted Diseases
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Abbott Laboratories
  • Bayer AG
  • F.Hoffmann-La Roche Ltd.
  • Qiagen N.V.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • BioMerieux S.A.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Nova Biomedical Corporation
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo